CN111662237A - [2-(5′-氟尿嘧啶)乙酸-吡咯烷基二硫代氨基甲酸]酐及在制备抗癌药物中的应用 - Google Patents
[2-(5′-氟尿嘧啶)乙酸-吡咯烷基二硫代氨基甲酸]酐及在制备抗癌药物中的应用 Download PDFInfo
- Publication number
- CN111662237A CN111662237A CN202010572843.4A CN202010572843A CN111662237A CN 111662237 A CN111662237 A CN 111662237A CN 202010572843 A CN202010572843 A CN 202010572843A CN 111662237 A CN111662237 A CN 111662237A
- Authority
- CN
- China
- Prior art keywords
- fluorouracil
- compound
- preparation
- pyrrolidinyl
- dithiocarbamate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229960002949 fluorouracil Drugs 0.000 title claims abstract description 29
- 150000008064 anhydrides Chemical class 0.000 title claims abstract description 22
- 238000002360 preparation method Methods 0.000 title claims abstract description 14
- 239000002246 antineoplastic agent Substances 0.000 title claims abstract description 10
- 229940041181 antineoplastic drug Drugs 0.000 title abstract description 9
- 150000001875 compounds Chemical class 0.000 claims abstract description 24
- 210000004881 tumor cell Anatomy 0.000 claims abstract description 15
- JPVYNHNXODAKFH-UHFFFAOYSA-N Cu2+ Chemical compound [Cu+2] JPVYNHNXODAKFH-UHFFFAOYSA-N 0.000 claims abstract description 10
- 229910001431 copper ion Inorganic materials 0.000 claims abstract description 10
- 239000012990 dithiocarbamate Substances 0.000 claims abstract description 10
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 6
- 239000003814 drug Substances 0.000 claims description 14
- 230000001394 metastastic effect Effects 0.000 claims description 3
- 206010061289 metastatic neoplasm Diseases 0.000 claims description 3
- 230000004614 tumor growth Effects 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000002062 proliferating effect Effects 0.000 claims 1
- 210000004027 cell Anatomy 0.000 abstract description 27
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 abstract description 18
- 230000000694 effects Effects 0.000 abstract description 11
- 230000015572 biosynthetic process Effects 0.000 abstract description 10
- 231100000263 cytotoxicity test Toxicity 0.000 abstract description 10
- 238000002474 experimental method Methods 0.000 abstract description 9
- 230000000259 anti-tumor effect Effects 0.000 abstract description 7
- 238000003786 synthesis reaction Methods 0.000 abstract description 6
- 230000004663 cell proliferation Effects 0.000 abstract description 2
- 238000013461 design Methods 0.000 abstract description 2
- 239000000126 substance Substances 0.000 abstract description 2
- 206010027476 Metastases Diseases 0.000 abstract 2
- 230000005764 inhibitory process Effects 0.000 abstract 2
- 230000009401 metastasis Effects 0.000 abstract 2
- 238000001212 derivatisation Methods 0.000 abstract 1
- -1 dithiocarbamate compound Chemical class 0.000 abstract 1
- 239000002547 new drug Substances 0.000 abstract 1
- WFYXUCXMDGRLJZ-UHFFFAOYSA-N pyrrolidin-1-ylazanium;carbamodithioate Chemical compound NC(S)=S.NN1CCCC1 WFYXUCXMDGRLJZ-UHFFFAOYSA-N 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 15
- 239000002609 medium Substances 0.000 description 14
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 10
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 8
- 229940079593 drug Drugs 0.000 description 8
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 7
- 239000010949 copper Substances 0.000 description 7
- 229930182555 Penicillin Natural products 0.000 description 6
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 6
- 229940049954 penicillin Drugs 0.000 description 6
- 238000003860 storage Methods 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 5
- 239000012894 fetal calf serum Substances 0.000 description 5
- 239000001963 growth medium Substances 0.000 description 5
- LGIWQUXJCCGZOC-UHFFFAOYSA-N pyrrolidin-1-yl carbamodithioate Chemical compound NC(=S)SN1CCCC1 LGIWQUXJCCGZOC-UHFFFAOYSA-N 0.000 description 5
- 229960005322 streptomycin Drugs 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 230000003833 cell viability Effects 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 238000005160 1H NMR spectroscopy Methods 0.000 description 3
- CPMUSDZOVZYEJJ-UHFFFAOYSA-N 2-(5-fluoro-2,4-dioxopyrimidin-1-yl)acetic acid Chemical compound OC(=O)CN1C=C(F)C(=O)NC1=O CPMUSDZOVZYEJJ-UHFFFAOYSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- VSWDORGPIHIGNW-UHFFFAOYSA-N Pyrrolidine dithiocarbamic acid Chemical compound SC(=S)N1CCCC1 VSWDORGPIHIGNW-UHFFFAOYSA-N 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 239000012346 acetyl chloride Substances 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 239000006285 cell suspension Substances 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 239000012091 fetal bovine serum Substances 0.000 description 3
- 239000012679 serum free medium Substances 0.000 description 3
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- OCUCCJIRFHNWBP-IYEMJOQQSA-L Copper gluconate Chemical compound [Cu+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O OCUCCJIRFHNWBP-IYEMJOQQSA-L 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 102000003945 NF-kappa B Human genes 0.000 description 2
- 108010057466 NF-kappa B Proteins 0.000 description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 2
- MEUUNENZOSPGDT-UHFFFAOYSA-N [K].FC=1C(NC(NC1)=O)=O Chemical compound [K].FC=1C(NC(NC1)=O)=O MEUUNENZOSPGDT-UHFFFAOYSA-N 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 201000010881 cervical cancer Diseases 0.000 description 2
- 239000013522 chelant Substances 0.000 description 2
- 229940108925 copper gluconate Drugs 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 210000003739 neck Anatomy 0.000 description 2
- 230000003285 pharmacodynamic effect Effects 0.000 description 2
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 1
- 206010004146 Basal cell carcinoma Diseases 0.000 description 1
- 206010051779 Bone marrow toxicity Diseases 0.000 description 1
- 206010048610 Cardiotoxicity Diseases 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- 108090000371 Esterases Proteins 0.000 description 1
- 208000022072 Gallbladder Neoplasms Diseases 0.000 description 1
- 208000032612 Glial tumor Diseases 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010029350 Neurotoxicity Diseases 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 101000693619 Starmerella bombicola Lactone esterase Proteins 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 206010044221 Toxic encephalopathy Diseases 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 229910052787 antimony Inorganic materials 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 229910052785 arsenic Inorganic materials 0.000 description 1
- VFBDWVWTIWQCOQ-UHFFFAOYSA-N azane;pyrrolidin-1-ylcarbamodithioic acid Chemical compound [NH4+].[S-]C(=S)NN1CCCC1 VFBDWVWTIWQCOQ-UHFFFAOYSA-N 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 231100000366 bone marrow toxicity Toxicity 0.000 description 1
- BQRGNLJZBFXNCZ-UHFFFAOYSA-N calcein am Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC(CN(CC(=O)OCOC(C)=O)CC(=O)OCOC(C)=O)=C(OC(C)=O)C=C1OC1=C2C=C(CN(CC(=O)OCOC(C)=O)CC(=O)OCOC(=O)C)C(OC(C)=O)=C1 BQRGNLJZBFXNCZ-UHFFFAOYSA-N 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- DKVNPHBNOWQYFE-UHFFFAOYSA-N carbamodithioic acid Chemical compound NC(S)=S DKVNPHBNOWQYFE-UHFFFAOYSA-N 0.000 description 1
- 229910002091 carbon monoxide Inorganic materials 0.000 description 1
- 231100000259 cardiotoxicity Toxicity 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 210000003679 cervix uteri Anatomy 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- PQJJJMRNHATNKG-UHFFFAOYSA-N ethyl bromoacetate Chemical compound CCOC(=O)CBr PQJJJMRNHATNKG-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 201000010175 gallbladder cancer Diseases 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 229910052745 lead Inorganic materials 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 208000026037 malignant tumor of neck Diseases 0.000 description 1
- 229910052748 manganese Inorganic materials 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000007135 neurotoxicity Effects 0.000 description 1
- 231100000228 neurotoxicity Toxicity 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 108700038606 rat Smooth muscle Proteins 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 208000003265 stomatitis Diseases 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 238000009210 therapy by ultrasound Methods 0.000 description 1
- 229910052718 tin Inorganic materials 0.000 description 1
- 229910021642 ultra pure water Inorganic materials 0.000 description 1
- 239000012498 ultrapure water Substances 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/52—Two oxygen atoms
- C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
- C07D239/545—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/553—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms with halogen atoms or nitro radicals directly attached to ring carbon atoms, e.g. fluorouracil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims (5)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010572843.4A CN111662237B (zh) | 2020-06-22 | 2020-06-22 | [2-(5′-氟尿嘧啶)乙酸-吡咯烷基二硫代氨基甲酸]酐及在制备抗癌药物中的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010572843.4A CN111662237B (zh) | 2020-06-22 | 2020-06-22 | [2-(5′-氟尿嘧啶)乙酸-吡咯烷基二硫代氨基甲酸]酐及在制备抗癌药物中的应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN111662237A true CN111662237A (zh) | 2020-09-15 |
CN111662237B CN111662237B (zh) | 2021-04-23 |
Family
ID=72389230
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010572843.4A Active CN111662237B (zh) | 2020-06-22 | 2020-06-22 | [2-(5′-氟尿嘧啶)乙酸-吡咯烷基二硫代氨基甲酸]酐及在制备抗癌药物中的应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN111662237B (zh) |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1969820A (zh) * | 2006-12-12 | 2007-05-30 | 济南帅华医药科技有限公司 | 抗癌药物组合物 |
US20100166881A1 (en) * | 2005-10-27 | 2010-07-01 | Prendergast George C | Novel IDO Inhibitors and Methods of Use Thereof |
CN102391191A (zh) * | 2011-09-01 | 2012-03-28 | 首都师范大学 | 2,4-二氨基喹唑啉的哌嗪二硫代甲酸酯衍生物及其制备方法和抗肿瘤用途 |
CN107226789A (zh) * | 2017-05-09 | 2017-10-03 | 北京大学 | 氨基二硫代甲酸酯类化合物、其制备方法以及在制备抗肿瘤药物中的用途 |
CN109232477A (zh) * | 2018-10-29 | 2019-01-18 | 郑州大学 | 查尔酮-氨基二硫代甲酸酯类过氧化氢酶抑制剂及其合成方法和应用 |
CN110330474A (zh) * | 2019-07-11 | 2019-10-15 | 北京师范大学 | 芹菜素-二硫代氨基甲酸酯类衍生物制备及抗肿瘤应用 |
-
2020
- 2020-06-22 CN CN202010572843.4A patent/CN111662237B/zh active Active
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100166881A1 (en) * | 2005-10-27 | 2010-07-01 | Prendergast George C | Novel IDO Inhibitors and Methods of Use Thereof |
CN1969820A (zh) * | 2006-12-12 | 2007-05-30 | 济南帅华医药科技有限公司 | 抗癌药物组合物 |
CN102391191A (zh) * | 2011-09-01 | 2012-03-28 | 首都师范大学 | 2,4-二氨基喹唑啉的哌嗪二硫代甲酸酯衍生物及其制备方法和抗肿瘤用途 |
CN107226789A (zh) * | 2017-05-09 | 2017-10-03 | 北京大学 | 氨基二硫代甲酸酯类化合物、其制备方法以及在制备抗肿瘤药物中的用途 |
CN109232477A (zh) * | 2018-10-29 | 2019-01-18 | 郑州大学 | 查尔酮-氨基二硫代甲酸酯类过氧化氢酶抑制剂及其合成方法和应用 |
CN110330474A (zh) * | 2019-07-11 | 2019-10-15 | 北京师范大学 | 芹菜素-二硫代氨基甲酸酯类衍生物制备及抗肿瘤应用 |
Non-Patent Citations (2)
Title |
---|
ALFREDO GINER-SOROLLA等: "Synthesis and properties of 5-mercaptomethyluracil and related derivatives", 《JOURNAL OF MEDICINAL CHEMISTRY》 * |
苗艳: "新型香豆素衍生物的合成与抗增殖活性研究", 《华中师范大学硕士学位论文》 * |
Also Published As
Publication number | Publication date |
---|---|
CN111662237B (zh) | 2021-04-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN107955042B (zh) | 具有抗癌活性的铂类配合物、制备方法及应用 | |
CN107286199B (zh) | 一种双核芳基钌金属配合物及其合成方法和应用 | |
CN111393483B (zh) | 一种四价铂萘酰亚胺配合物、其制备方法及应用 | |
Yang et al. | Improvement in the anticancer activity of 6-mercaptopurine via combination with bismuth (III) | |
CN113072595B (zh) | 一种低毒性Pt配合物及其制备方法与应用 | |
CN111592498B (zh) | [2-(5′-氟尿嘧啶)乙酸-二乙基二硫代氨基甲酸]酐及在制备抗癌药物中的应用 | |
CN111662237B (zh) | [2-(5′-氟尿嘧啶)乙酸-吡咯烷基二硫代氨基甲酸]酐及在制备抗癌药物中的应用 | |
CN111072725B (zh) | 一种具有萘普生四价铂结构的化合物、制备方法及其在制备抗肿瘤药物中的应用 | |
CN104774221A (zh) | 喹啉酮衍生物的金属配合物及其合成方法及应用 | |
CN106083925B (zh) | 一种二膦酸化合物及其制备方法与应用 | |
CN107501303B (zh) | 一种布洛芬与喹啉-8-甲醛席夫碱构筑的铜(ii)配合物及其合成方法和应用 | |
CN107827934B (zh) | 具有抗癌活性的四价铂配合物、制备方法及应用 | |
CN111825623B (zh) | [2-(5′-氟尿嘧啶)乙酸-(n-乙基)哌嗪基二硫代氨基甲酸]酐及其应用 | |
CN112940059B (zh) | 一种糖基修饰的萘酰亚胺-多胺缀合物、其制备方法及应用 | |
CN112125925B (zh) | 抗肿瘤化合物噻唑烷酮双核铜化合物的制备方法 | |
CN111518037B (zh) | [2-(5′-氟尿嘧啶)乙酸-乙基苯基二硫代氨基甲酸]酐及在制备抗癌药物中的应用 | |
CN105440085A (zh) | 9-苯并噻蒽腙-钌(ii)配合物及其合成方法和应用 | |
CN104725431A (zh) | 喹啉酮衍生物的钴(ⅱ)配合物及其合成方法及应用 | |
CN108164476B (zh) | 间苯二腈类化合物、其应用以及包含该化合物的药物 | |
CN105481944B (zh) | 一种苯并咪唑衍生物二肽铜配合物及其制备方法和应用 | |
CN112010791B (zh) | 含苯磺酰胺结构单元的新型苯乙酸紫草宁酯类衍生物及其合成方法和应用 | |
CN113024450B (zh) | 一种二硫代甲酯钴(iii)配合物及其制备方法和应用 | |
CN110357926B (zh) | 环庚三烯酚酮与邻菲啰啉混配锰配合物及其制备方法和应用 | |
CN110981897A (zh) | 一种锌(ii)配合物、合成方法及其在抗肿瘤药物中的应用 | |
CN104558051A (zh) | 一种以2-苯甲酰基吡啶为配体的铑(ii)配合物及其合成方法和应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20200915 Assignee: WUHAN MADESIN PHARMACEUTICAL TECHNOLOGY CO.,LTD. Assignor: HUBEI University OF TECHNOLOGY Contract record no.: X2023980047209 Denomination of invention: [2- (5 '- fluorouracil) acetic acid pyrrolidyl dithiocarbamate] anhydride and its application in the preparation of anticancer drugs Granted publication date: 20210423 License type: Common License Record date: 20231121 Application publication date: 20200915 Assignee: TAILITE MEDICINE (HUBEI) CO.,LTD. Assignor: HUBEI University OF TECHNOLOGY Contract record no.: X2023980047204 Denomination of invention: [2- (5 '- fluorouracil) acetic acid pyrrolidyl dithiocarbamate] anhydride and its application in the preparation of anticancer drugs Granted publication date: 20210423 License type: Common License Record date: 20231120 |
|
EE01 | Entry into force of recordation of patent licensing contract |